NICE recommends the tablets for adults with moderate to severe fibroid symptoms. Linzagolix is recommended for longer-term treatment, with the dose depending on the patient. For endometriosis, they ...

Innovative AI technologies have the potential to act like a ‘second pair of eyes’, helping radiologists review prostate MRI scans.

Prescribing of NICE-recommended tablets for endometriosis and fibroids has more than tripled in a year across England, giving thousands of additional women another option to manage painful and ...

All NICE products on prostate cancer. Includes any guidance, advice and quality standards.

NICE is unable to make a recommendation on lurbinectedin (Zepzelca) with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer in adults. This is because the company ...

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...

We have moved interventional procedures guidance 666 to become HealthTech guidance 535. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment ...

NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not ...

This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life. NICE has also produced a ...

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...

Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults. There is a commercial access agreement ...

Evidence-based recommendations on secukinumab (Cosentyx) for moderate to severe plaque psoriasis in children and young people aged 6 to 17 years. Next review: This guidance will be reviewed if there ...